HKEX Stock Code: 01093English|繁體|简体
Home > Investor Relations > Announcements & Notices
Announcements & Notices
May
31
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 31 MAY 2023
May
30
VOLUNTARY ANNOUNCEMENT - CLINICAL DATA OF ALMB-0168 FOR THE TREATMENT OF OSTEOSARCOMA TO BE PRESENTED AT THE 2023 ASCO ANNUAL MEETING
May
30
GRANT OF SHARE AWARDS PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY
May
25
QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2023
May
15
DATE OF BOARD MEETING
Apr
26
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF PRUSOGLIPTIN TABLETS
Apr
26
NOTICE OF ANNUAL GENERAL MEETING
Apr
25
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2023
Apr
20
VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6010 OBTAINS CLINICAL TRIAL APPROVAL
Apr
02
VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE CPO301 OBTAINS CLINIAL TRIAL APPROVAL IN THE U.S.
Mar
27
VOLUNTARY ANNOUNCEMENT - "APREMILAST TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Mar
22
CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER
Mar
22
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2022
Mar
22
VOLUNTARY ANNOUNCEMENT - SARS-CoV-2 mRNA VACCINE (SYS6006) INCLUDED FOR EMERGENCY USE IN CHINA
Mar
16
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2022
Mar
10
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF ENLONSTOBART FOR INJECTION
Mar
10
DATE OF BOARD MEETING
Mar
02
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE III CLINICAL TRIAL OF DUOENDA (MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION) FOR THE TREATMENT OF RECURRENT METASTATIC NASOPHARYNGEAL CARCINOMA
Feb
23
REMUNERATION COMMITTEE - TERMS OF REFERENCE
Feb
23
NOMINATION COMMITTEE - TERMS OF REFERENCE
Feb
16
VOLUNTARY ANNOUNCEMENT - NBL-020 FOR THE TREATMENT OF ADVANCED SOLID TUMORS OBTAINS CLINIAL TRIAL APPROVAL IN CHINA
Feb
13
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR SYS6002 WITH CORBUS PHARMACEUTICALS
Jan
19
VOLUNTARY ANNOUNCEMENT - OCTREOTIDE LONG-ACTING INJECTION OBTAINS CLINICAL TRIAL APPROVAL
Jan
09
VOLUNTARY ANNOUNCEMENT - CLEVIDIPINE INJECTABLE EMULSION OBTAINS CLINICAL TRIAL APPROVAL
Jan
05
VOLUNTARY ANNOUNCEMENT - MELOXICAM NANOCRYSTAL INJECTION OBTAINS CLINICAL TRIAL APPROVAL
Jan
04
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE PRMT5 INHIBITOR SYH2045 OBTAINS CLINICAL TRIAL APPROVAL

Please download the latest "Acrobat Reader" to view the PDF.

© Copyright 2023 CSPC Pharmaceutical Group Limited. All Rights Reserved.
Disclaimer